To assess the frequency and molecular polymorphism of malignancy-associated latent membrane protein 1 (LMP1) variants in human immunodeficiency virus type 1 (HIV-1) infection, 94 B-lymphoblastoid cell lines spontaneously derived from peripheral blood mononuclear cells (PBMC) and 30 PBMC samples at seroconversion and later (mean, 55 months) were analyzed by longitudinal comparative sequence analysis in 8 patients progressing to nonHodgkin's lymphoma (AIDS-NHL), 7 patients to opportunistic infections, and 2 patients with long-term asymptomatic HIV-1 infection. The sequence polymorphism in the C-terminus of LMP1 was characteristic for strains harbored by individual patients, with high fidelity for strain identification. In 14 of the 17 patients, two different but characteristic LMP1 variants were identified. At HIV seroconversion in 8 of 15 patients, a 30-bp deletion (LMP1D) was present. Though serial analysis revealed a shift to LMP1D in some individuals, statistical analysis of the cohort does not support the hypothesis that accumulation of LMP1D variants in PBMC accounts for their observed high incidence in AIDS-NHL.
The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is expressed in the tumor cells of EBV-associated malignancies, except Burkitt's lymphoma [1, 2] . LMP1 is considered a virus oncogene due to its ability to transform rodent fibroblasts in vitro and to render them tumorigenic in nude mice [3] . LMP1 induces DNA synthesis and expression of lymphocytic activation markers and adhesion molecules, and it upregulates bcl-2, resulting in extended survival of infected cells. Furthermore, it is engaged in cellular signaling processes of NF-kB and the tumor necrosis factor receptor family, including a mimicking of CD40 signaling (reviewed in [1, 4] ).
Naturally occurring carboxy terminal 30-bp deletion variants of LMP1 (LMP1D), first reported in nasopharyngeal carcinoma [5] , appear to be associated with enhanced oncogenic potential in vitro [6] . These deletions and clustered mutational hot spots within the C-terminal NF-kB activation domain of LMP1 were identified in a proportion of LMP1-expressing lymphomas but are also detected in healthy EBV carriers [4] . In the North American and European populations, LMP1D is observed in 170% of AIDS-related lymphomas but in significantly fewer asymptomatic EBV carriers [7] . However, it is not known whether such variants accumulate in the host in vivo. To address this question, we performed a comparative sequence analysis of the LMP1 C-terminus in 94 blood-derived B-lymphoblastoid cell lines (B-LCL) and 30 peripheral blood samples harvested from 17 individuals serially during human immunodeficiency virus type 1 (HIV-1) infection (over 14-113 months) to determine if the C-terminus of LMP1 is a molecular marker for EBV-strain identification.
Materials and Methods
Patients. Patients are participants of the Amsterdam Cohort studies on HIV-1 infection and AIDS. These individuals (homosexual men) at risk for HIV-1 infection were seen regularly until HIV-1 seroconversion and then followed thoroughly during HIV-1 infection. This study comprised 17 patients progressing to AIDS (CDC 1993 classification): 7 had an opportunistic infection, 1 had Hodgkin's disease, 7 had non-Hodgkin's lymphoma (NHL), and 2 were long-term asymptomatic (LTA) patients without HIV-1 progression over 16 years (1500 CD4 cells/mm 3 ). Clinical data have in part been reported elsewhere [8, 9] . Serial samples of peripheral blood mononuclear cells (PBMC) were harvested at different time points during the course of HIV-1 infection. B-LCL establishment. Spontaneous outgrowth of EBV-transformed B-LCL from PBMC was established as previously described [8] . Briefly, PBMC were resuspended in RPMI 1640 supplemented with 10% fetal calf serum, L-glutamine, antibiotics, and cyclosporin A (1 mg/L). Following serial dilutions starting at 0.5 ϫ 10 6 cells/ well, transformed cells from dilutions with !30% responding wells were expanded in vitro.
Polymerase chain reaction (PCR). Genomic DNA extracted from B-LCL clones or PBMC was used to identify the LMP1, LMP2A, and EBNA2 genomes. For PCR amplification and sequencing, the samples were numbered randomly, including a negative control and without knowledge of sample origin. For the amplification of the LMP1 C-terminus, three different primer sets were used as reported earlier [10] . The N-terminus of LMP2A, containing a repeated sequence of the immunoreceptor tyrosinebased activation motif [11] for EBNA2-B (EBNA2 type 2). Detailed methods describing PCR conditions and amplification strategies have been previously published [10] .
DNA sequencing. Double-stranded PCR products for the corresponding domains of LMP1 (obtained with primer pair 9/11: 5 -AGCGACTCTGCTGGAAATGAT-3 /5 -TGATTAGCTAAGG-CATTCCCA-3 [nt 168390-168370/168075-168095]) [10] , LMP2A, and EBNA2 were purified and directly sequenced with 35 S-dATP using a kit (Sequenase; Amersham Life Sciences, Arlington Heights, IL). Sequencing primers were primer 11 for LMP1, CB79 for LMP2A, and HK71 for EBNA2-A. For LMP1, LMP2A, and EBNA2, complementary DNA strands were sequenced in several cases and confirmed the initial sequencing data.
Statistical analysis. The uncorrected x 2 test was used to assess the association of LMP1 with the deletion variant (LMP1D) and LMP1 wild type (LMP1W) between samples of HIV seroconversion and AIDS diagnosis.
Nucleotide sequence accession numbers. The nucleotide sequences were submitted to GenBank under accession numbers AF085633 through AF085650.
Results

LMP1D
in different patient groups. PCR amplification of the LMP1 C-terminus with primer pair 9/11 at HIV-1 seroconversion revealed a product of wild type size (LMP1W) (strain B95.8, 316 bp) in 8 patients (table 1) , while at the same time point, for 3 patients, a PCR product of 286 bp indicated the presence of the 30-bp deletion variant (LMP1D). In PBMC and B-LCL samples of 6 patients, both LMP1W and LMP1D were identified. At AIDS diagnosis, LMP1W was found in 6 patients, LMP1D in 7, and both variants in 2. At a late time point (HIV-1-infected for 78 months), 1 of 2 HIV-LTA patients harbored LMP1D. The prevalence of the variant at seroconversion and at AIDS diagnosis did not differ significantly. However, 3 of 8 lymphoma patients had no more detectable copy numbers of LMP1W, which were easily identified at seroconversion.
Mutational hot spots in the LMP1 C-terminus describe a sequence variation specific for each patient. Sequence analysis of the LMP1 C-terminus performed in 94 B-LCL clones and 25 PBMC samples of 16 HIV-infected individuals is shown in detail in figure 1 . Sequencing confirmed the presence of the 30-bp deletion (nt 168285-168256) in all cases with a shorter PCR product. Samples from each patient showed a specific pattern of point mutations. PBMC and B-LCL clones derived from individual patients showed identical LMP1 sequences in 7; in 10 patients, the presence of a second specific LMP1 variant was detected.
Further characterization of virus strains from 2 patients with LMP1W and LMP1.
In 2 patients (AIDS-NHL5, HIV-LTA1) with accumulation of LMP1D over time, the virus strains were further characterized. The EBNA2 gene locus that discriminates EBV types A and B and the N-terminus of LMP2A were amplified and sequenced from early and late clones. Two early clones from patient AIDS-NHL5 with two point muta- tions in LMP1W were identified as EBNA2-A and carried four identical point mutations in LMP2A (nt 166750, T to G; 166796, C to A; 166805, A to C; and 166810, C to T). Three clones grown 4.2 years later were LMP1D and EBNA2-B and had those four mutations plus one more in LMP2A (166748, C to G). The PBMC samples harvested at lymphoma diagnosis and 2 months later carried LMP1D and 5 mutations in LMP2A. Primary PCR identified EBNA2-B weakly in one; however, after nested PCR, EBNA2-A and EBNA2-B were specifically amplified in both PBMC samples (data not shown).
Comparative sequence analysis of all 5 clones derived from patient HIV-LTA1 7.5 years after HIV-1 seroconversion demonstrated sequence identity in LMP2A (identical four point mutations at nt 166750, T to G; 166796, C to A; 166805, A to C; and 166810, C to T) and the EBNA2-A gene (identical point mutations at nt 48990, A to G; 48991, G to T; 48998, C to A; 49057, A to G; 49091, G to T; 49119, C to G; 49170, C to T; and an insertion of CTC between 49136/49137) in contrast to the LMP1 gene, where 2 LMP1W clones and 3 LMP1D clones were identified. So far, sequence polymorphisms in EBNA2 and LMP2A recognized an apparently unique strain with and without the 30-bp deletion variant. However, more extended analysis of the LMP1 gene in 4 clones identified also 2 strains: 1 with and the other without the 30-bp deletion, each linked to different numbers of internal 33-bp repeats (nt 168408-168573) and different sequence polymorphisms in the transmembranous segments (nt 168890-169020 and 169320-169435) of LMP1 (data not shown). Thus, LMP1 behaved as a marker for identification of virus strains, even in case of sequence identity in EBNA2 and LMP2A.
Discussion
A new, important finding of this study is the demonstration of the LMP1 C-terminus as an excellent molecular marker. Sequence variation in the carboxy terminus of LMP1 in 120 serial samples from 17 HIV-infected patients allowed us to differentiate individual viral variants and to establish the LMP1 C-terminus as a reliable sequence for strain identification. Longitudinal sequence analysis in a unique cohort of patients has proven the molecular stability of this identification region over several years. In particular, the strain-specific mutations and deletions, once identified in an EBV-infected individual, remain unchanged over several years. These findings extend previous data: Mutational hot spots encompassing deletions of 3, 12, 30, 63, and 69 bp [4] and insertions [7] not only characterize a hypervariable region (nt 168357-168225) but also remain unchanged once viral latency has been established. These deletion mutants, while maintaining full capacity to stimulate NF-kBmediated transcription, may enhance in vivo transformation of infected cells, since they occur in a region critical for the protein's half-life [4] . Indeed, high amounts of LMP1D protein have been identified in lymphomas with low LMP1 promoter activity [12] , suggesting prolonged half-life of such deletion variants.
The higher frequency of LMP1D in AIDS-related lymphoma compared with HIV-negative lymphomas and healthy EBV carriers was consistently reported in recent studies (reviewed in [4, 7] ), supporting the hypothesis that accumulation of LMP1D favored outgrowth of lymphoma. Though statistical analysis of our series did not validate this hypothesis, a change to a predominant LMP1D occurred in individual HIV patients progressing to lymphomas. Since our analysis also included patients with opportunistic infections and LTA survivors, a significant association of LMP1D with lymphoma may have been obscured.
Focussing on the patients harboring different viral variants, the shift to LMP1D during HIV infection in PBMC from 3 AIDS-NHL patients and in B-LCL from patients LTA1 and AIDS-NHL5 are of particular interest. In AIDS patients, expansion of the pool of EBV-infected cells, multistrain EBV infection, and EBV reactivation have been reported [13] . The HIV-induced progressing T cell deficiency allows EBV-infected B cells to proliferate as they do with B-LCL in vitro. We recently reported decreased EBV-specific cytotoxic T lymphocytes but significantly increased EBV load in several AIDS-NHL patients (including AIDS-NHL5) within 24 months prior to NHL diagnosis [8] . Thus, in the severely T cell-deficient host, cells infected with a coresident EBV strain carrying LMP1D may manifest a growth advantage analogous to that observed in vitro [6] , eventually resulting in lymphoma, as suggested for patient AIDS-NHL5.
In vivo evolution of the LMP1D variant could have happened in patient HIV-LTA1 without signs of HIV progression. This patient with 2 different strains had emergence of a new Cterminal LMP1 variant, proven by clonal outgrowth (in PBMC 98 months after HIV-1 seroconversion) and best explained by strain recombination occurring at the 5 -end of the 30-bp deletion. Indeed, viral inter-or intrastrain recombination during viral replication has been found in oral hairy leukoplakia [14] and in isolates from throat washings and PBMC of 2 HIVinfected patients [13] . In the early or latent stage of HIV disease, the virus has been shown to accumulate in lymph nodes, particularly in active germinal centers [15] , where chronic lymphoid stimulation allows productive replication that is presumed for viral recombination [1] .
These longitudinal data identify the LMP1 C-terminus as a reliable marker for the identification of viral variants. In longterm HIV-infected individuals, multistrain EBV infection, in vivo strain recombination, and growth advantage may contribute to the mosaic pattern observed in our study. However, the trend to the outgrowth of LMP1D/EBNA2B variants in patients progressing to lymphoma warrants prospective trials, including larger cohorts, to assess the clinical relevance of LMP1D, because this is at present the only EBV sequence var-iant known to be expressed in tumors and functionally linked to enhanced transforming potential.
